Northern Trust Corp Has $28.99 Million Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• Northern Trust Corp increased its holdings in LeMaitre Vascular by 5.4%, now owning 345,563 shares valued at approximately $28.99 million.
• LeMaitre Vascular reported a quarterly earnings per share of $0.60, exceeding analysts' expectations of $0.57, alongside a revenue increase of 15% year-over-year.
• The company announced a quarterly dividend of $0.20, resulting in an annualized dividend of $0.80 with a yield of 0.8%.

Northern Trust Corp increased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 345,563 shares of the medical instruments supplier's stock after buying an additional 17,748 shares during the quarter. Northern Trust Corp owned 1.53% of LeMaitre Vascular worth $28,993,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Avantax Advisory Services Inc. grew its position in LeMaitre Vascular by 1.5% during the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier's stock worth $1,261,000 after buying an additional 229 shares in the last quarter. HighTower Advisors LLC grew its position in LeMaitre Vascular by 4.2% in the first quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier's stock valued at $497,000 after acquiring an additional 237 shares during the period. Fifth Third Bancorp raised its stake in LeMaitre Vascular by 2.3% during the first quarter. Fifth Third Bancorp now owns 10,903 shares of the medical instruments supplier's stock worth $915,000 after acquiring an additional 246 shares in the last quarter. Cetera Investment Advisers raised its stake in LeMaitre Vascular by 11.5% during the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock worth $254,000 after acquiring an additional 284 shares in the last quarter. Finally, Opal Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the first quarter worth $26,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 3.0%

LMAT stock traded up $2.80 during trading on Thursday, hitting $97.36. The company had a trading volume of 62,672 shares, compared to its average volume of 189,640. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $88.05 and a 200-day moving average price of $86.35. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of 47.26, a PEG ratio of 2.45 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same quarter in the previous year, the company posted $0.52 EPS. LeMaitre Vascular's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular's payout ratio is presently 38.83%.

Analyst Ratings Changes

Several research analysts have issued reports on LMAT shares. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald lifted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $97.60.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of the company's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director owned 2,916 shares in the company, valued at approximately $274,104. The trade was a 46.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the business's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at $269,875.80. This trade represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.